CNS Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for neurology and oncology. Historically centered on glioblastoma multiforme (GBM) with investigational compounds TPI 287 and Berubicin, the company pivoted in March 2026 to a broader strategy of acquiring or in-licensing differentiated preclinical and clinical-stage assets in neurology and oncology, while exploring out-licensing of its legacy GBM compounds.
Q2 FY2026 — expected 2026-07-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001683168-26-002550 | EDGAR | 43K words |
| 2025-03-31 | 2024-12-31 | 0001683168-25-002139 | EDGAR | 47K words |
| 2024-04-01 | 2023-12-31 | 0001683168-24-002032 | EDGAR | 46K words |
| 2023-03-31 | 2022-12-31 | 0001683168-23-002086 | EDGAR | — |
| 2022-03-03 | 2021-12-31 | 0001683168-22-001401 | EDGAR | — |
| 2021-02-12 | 2020-12-31 | 0001683168-21-000533 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001683168-20-000781 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-12 | 2026-06-30 | 0001683168-26-006224 | EDGAR | 13K words |
| 2025-11-14 | 2025-09-30 | 0001683168-25-008466 | EDGAR | 14K words |
| 2025-08-14 | 2025-06-30 | 0001683168-25-006162 | EDGAR | 14K words |
| 2025-05-15 | 2025-03-31 | 0001683168-25-003733 | EDGAR | 12K words |
| 2024-11-14 | 2024-09-30 | 0001683168-24-008125 | EDGAR | 18K words |
| 2024-08-14 | 2024-06-30 | 0001683168-24-005711 | EDGAR | 17K words |
| 2024-05-15 | 2024-03-31 | 0001683168-24-003531 | EDGAR | 15K words |
| 2023-11-14 | 2023-09-30 | 0001683168-23-008144 | EDGAR | 15K words |
| 2023-08-14 | 2023-06-30 | 0001683168-23-005609 | EDGAR | 14K words |
| 2023-05-15 | 2023-03-31 | 0001683168-23-003311 | EDGAR | 13K words |
| 2022-11-10 | 2022-09-30 | 0001683168-22-007532 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001683168-22-005637 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-11 | 0001683168-26-001664 | EDGAR | 1K words |
| 2026-03-02 | 0001683168-26-001413 | EDGAR | 5K words |
| 2026-02-17 | 0001683168-26-001066 | EDGAR | 5K words |
| 2025-12-17 | 0001683168-25-009208 | EDGAR | 5K words |
| 2025-11-21 | 0001683168-25-008624 | EDGAR | 7K words |
| 2025-07-22 | 0001683168-25-005284 | EDGAR | 1K words |
| 2025-07-15 | 0001683168-25-005129 | EDGAR | 1K words |
| 2025-05-15 | 0001683168-25-003575 | EDGAR | 22K words |
| 2025-04-09 | 0001683168-25-002373 | EDGAR | 2K words |
| 2025-03-31 | 0001683168-25-002140 | EDGAR | 1K words |
169 total filings indexed. 140 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001729427 |
| Ticker | CNSP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.cnspharma.com |
| Listed | 2019-11-08 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CNSP (~200 tokens, structured JSON with cryptographic provenance)